Continuing Education Activity

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. The American Psychiatric Association’s Diagnostic Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) classifies the depressive disorders into Disruptive mood dysregulation disorder; Major depressive disorder; Persistent depressive disorder (dysthymia); Premenstrual dysphoric disorder; and Depressive disorder due to another medical condition. The common features of all the depressive disorders are sadness, emptiness, or irritable mood, accompanied by somatic and cognitive changes that significantly affect the individual’s capacity to function. This activity reviews the evaluation and management of depression and the role of interprofessional team members in collaborating to provide well-coordinated care and enhance patient outcomes.

Objectives:

• Review the risk factors for depression.
• Describe DSM V criteria for the diagnosis of depression.
• Summarize the treatment of depression.
• Outline the evaluation and management of depression and the role of interprofessional team members in collaborating to provide well-coordinated care and enhance patient outcomes.

Introduction

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest.[1][2] The American Psychiatric Association’s Diagnostic Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) classifies the depressive disorders into:

1. Disruptive mood dysregulation disorder
2. Major depressive disorder
3. Persistent depressive disorder (dysthymia)
4. Premenstrual dysphoric disorder
5. Depressive disorder due to another medical condition

The common features of all the depressive disorders are sadness, emptiness, or irritable mood, accompanied by somatic and cognitive changes that significantly affect the individual’s capacity to function.[3]

Because of false perceptions, nearly 60% of people with depression do not seek medical help. Many feel that the stigma of a mental health disorder is not acceptable in society and may hinder both personal and professional life. There is good evidence indicating that most antidepressants do work but the individual response to treatment may vary. 

Etiology

The etiology of major depressive disorder is multifactorial with both genetic and environmental factors playing a role. First-degree relatives of depressed individuals are about 3 times as likely to develop depression as the general population; however, depression can occur in people without family histories of depression.[4][5]

Some evidence suggests that genetic factors play a lesser role in late-onset depression than in early-onset depression. There are potential biological risk factors that have been identified for depression in the elderly. Neurodegenerative diseases (especially Alzheimer disease and Parkinson disease), stroke, multiple sclerosis, seizure disorders, cancer, macular degeneration, and chronic pain have been associated with higher rates of depression. Life events and hassles operate as triggers for the development of depression. Traumatic events such as the death or loss of a loved one, lack or reduced social support, caregiver burden, financial problems, interpersonal difficulties, and conflicts are examples of stressors that can trigger depression.

Epidemiology

Twelve-month prevalence of major depressive disorder is approximately 7%, with marked differences by age group.  The prevalence in 18- to 29-year-old individuals is threefold higher than the prevalence in individuals aged 60 years or older. Females experience 1.5- to 3-fold higher rates than males beginning in early adolescence.  In the US, depression affects nearly 17 million adults but these numbers are gross underestimates as many have not even come to medical attention.

Pathophysiology

The underlying pathophysiology of major depressive disorder has not been clearly defined. Current evidence points to a complex interaction between neurotransmitter availability and receptor regulation and sensitivity underlying the affective symptoms.

Clinical and preclinical trials suggest a disturbance in central nervous system serotonin (5-HT) activity as an important factor. Other neurotransmitters implicated include norepinephrine (NE), dopamine (DA), glutamate, and brain-derived neurotrophic factor (BDNF).

The role of CNS 5-HT activity in the pathophysiology of major depressive disorder is suggested by the therapeutic efficacy of selective serotonin reuptake inhibitors (SSRIs). Research findings imply a role for neuronal receptor regulation, intracellular signaling, and gene expression over time, in addition to enhanced neurotransmitter availability.

Seasonal affective disorder is a form of major depressive disorder that typically arises during the fall and winter and resolves during the spring and summer. Studies suggest that seasonal affective disorder is also mediated by alterations in CNS levels of 5-HT and appears to be triggered by alterations in circadian rhythm and sunlight exposure.

Vascular lesions may contribute to depression by disrupting the neural networks involved in emotion regulation—in particular, frontostriatal pathways that link the dorsolateral prefrontal cortex, orbitofrontal cortex, anterior cingulate, and dorsal cingulate. Other components of limbic circuitry, in particular, the hippocampus and amygdala, have been implicated in depression.

History and Physical

The investigation into depressive symptoms begins with inquiries of the neurovegetative symptoms which include changes in sleeping patterns, appetite, and energy levels. Positive responses should elicit further questioning focused on evaluating for the presence of the symptoms which are diagnostic of major depression. These are the 9 symptoms listed in the DSM-5. Five must be present to make the diagnosis (one of the symptoms should be depressed mood or loss of interest or pleasure):

1. Sleep disturbance
2. Interest/pleasure reduction
3. Guilt feelings or thoughts of worthlessness
4. Energy changes/fatigue
5. Concentration/attention impairment
6. Appetite/weight changes
7. Psychomotor disturbances
8. Suicidal thoughts
9. Depressed mood

All patients with depression should be evaluated for suicidal risk. Any suicide risk must be given prompt attention which could include hospitalization or close and frequent monitoring.

Other areas of investigation include:

1. Past medical history and family medical history, and current medications
2. Social history with a focus on stressors and the use of drugs and alcohol
3. History and physical examination to rule out organic causes of depression. Depressive symptoms and their severity are also evaluated with the help of questionnaires such as the Beck's Depression Inventory (BDI), Hamilton Depression Scale (Ham-D), and Zung Self Rating Depression Scale

Evaluation

The diagnosis of depression is based on history and physical findings. No diagnostic laboratory tests are available to diagnose major depressive disorder. Laboratory studies are, however, useful to exclude medical illnesses that may present as major depressive disorder. [6][7][8]These laboratory studies might include the following:

• Complete blood cell (CBC) count
• Thyroid-stimulating hormone (TSH)
• Vitamin B-12
• Rapid plasma reagin (RPR)
• HIV test
• Electrolytes, including calcium, phosphate, and magnesium levels
• Blood urea nitrogen (BUN) and creatinine
• Liver function tests (LFTs)
• Blood alcohol level
• Blood and urine toxicology screen
• Arterial blood gas (ABG)
• Dexamethasone suppression test (Cushing disease, but also positive in depression)
• Cosyntropin (ACTH) stimulation test (Addison disease)  
• Computed tomography (CT) scanning or magnetic resonance imaging (MRI) of the brain should be considered if organic brain syndrome or hypopituitarism is included in the differential diagnosis

Treatment / Management

Medication alone and brief psychotherapy (cognitive-behavioral therapy, interpersonal therapy) alone can relieve depressive symptoms. Combination therapy has also been associated with significantly higher rates of improvement in depressive symptoms; increased quality of life; and better treatment compliance. There is also empirical support for the ability of CBT to prevent relapse.[9][10]

Electroconvulsive therapy is useful for patients who are not responding well to medications or are suicidal.[11][1]

Medications

1. Selective serotonin reuptake inhibitors (SSRIs)
2. Serotonin/norepinephrine reuptake inhibitors (SNRIs)     
3. Atypical antidepressants
4. Serotonin-Dopamine Activity Modulators (SDAMs)     
5. Tricyclic antidepressants (TCAs)
6. Monoamine oxidase inhibitors (MAOIs)  
7. Selective serotonin reuptake inhibitors (SSRIs): SSRIs have the advantage of ease of dosing and low toxicity in overdose. They are also the first-line medications for late-onset depression.
8. SSRIs include: Citalopram, escitalopram, fluoxetine,  fluvoxamine, paroxetine, sertraline, vilazodone, vortioxetine
9. Serotonin/norepinephrine reuptake inhibitors (SNRIs): SNRIs, which include venlafaxine, desvenlafaxine, duloxetine, and levomilnacipran can be used as first-line agents, particularly in patients with significant fatigue or pain syndromes associated with the episode of depression. SNRIs also have an important role as second-line agents in patients who have not responded to SSRIs. 
10. Atypical antidepressants: Atypical antidepressants include bupropion, mirtazapine, nefazodone, and trazodone. They have all been found to be effective in monotherapy in major depressive disorder and may be used in combination therapy for more difficult to treat depression.
11. Serotonin-Dopamine Activity Modulators (SDAMs): SDAMs include brexpiprazole and aripiprazole. SDAMs act as a partial agonist at 5-HT1A and dopamine D2 receptors at similar potency, and as an antagonist at 5-HT2A and noradrenaline alp Brexpiprazole is indicated as adjunctive therapy for major depressive disorder (MDD).
12. Tricyclic antidepressants (TCAS): TCAs include the following: Amitriptyline, clomipramine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, trimipramine. TCAs have a long record of efficacy in the treatment of depression. They are used less commonly because of their side-effect profile and their considerable toxicity in overdose.
13. Monoamine oxidase inhibitors (MAOIs): MAOIs include isocarboxazid, phenelzine, selegiline, and tranylcypromine. These agents are widely effective in a broad range of affective and anxiety disorders. Because of the risk of hypertensive crisis, patients on these medications must follow a low-tyramine diet. Other adverse effects can include insomnia, anxiety, orthostasis, weight gain, and sexual dysfunction.

Electroconvulsive Therapy (ECT)

ECT is a highly effective treatment for depression. Onset of action may be more rapid than that of drug treatments, with benefit often seen within 1 week of commencing treatment. A course of ECT (usually up to 12 sessions) is the treatment of choice for patients who do not respond to drug therapy, are psychotic, or are suicidal or dangerous to themselves. Thus, the indications for the use of ECT include the following:

1. Need for a rapid antidepressant response  Failure of drug therapies   
2. History of a good response to ECT     
3. Patient preference     
4. High risk of suicide
5. High risk of medical morbidity and mortality

Although advances in brief anesthesia and neuromuscular paralysis have improved the safety and tolerability of ECT, this modality poses numerous risks, including those associated with general anesthesia, postictal confusion, and, more rarely, short-term memory difficulties.  

Psychotherapy

Cognitive Behavior Therapy and Interpersonal Therapy are evidence-based psychotherapies that have been found to be effective in the treatment of depression.

Cognitive-behavioral therapy (CBT)

CBT is a structured, and didactic form of therapy that focuses on helping individuals identify and modify maladaptive thinking and behavior patterns (16 to 20 sessions). It is based on the premise that patients who are depressed exhibit the “cognitive triad” of depression, which includes a negative view of themselves, the world, and the future. Patients with depression also exhibit cognitive distortions that help to maintain their negative beliefs. CBT for depression typically includes behavioral strategies (i.e., activity scheduling), as well as cognitive restructuring to change negative automatic thoughts and addressing maladaptive schemas.

There is evidence supporting the use of CBT with individuals of all ages. It is also considered being efficacious for the prevention of relapse. It is particularly valuable for elderly patients, who may be more prone to problems or side effects with medications.  

Mindfulness-based cognitive therapy (MBCT) was designed to reduce relapse among individuals who have been successfully treated for an episode of recurrent major depressive disorder. The primary treatment component is mindfulness training. MBCT specifically focuses on ruminative thought processes as being a risk factor for relapse. Research indicates that MBCT is effective in reducing the risk of relapse in patients with recurrent depression, especially in those with the most severe residual symptoms. Interpersonal therapy (IPT)

Interpersonal Therapy (IPT)

Interpersonal therapy (IPT) is a time-limited (typically 16 sessions) treatment for major depressive disorder. IPT draws from attachment theory and emphasize the role of interpersonal relationships, focusing on current interpersonal difficulties. Specific areas of emphasis include grief, interpersonal disputes, role transitions, and interpersonal deficits.

Differential Diagnosis

• Adjustment disorders

• Anaemia

• Chronic Fatigue syndrome

• Dissociative disorders

• Illness anxiety disorders

• Hypoglycemia

• Hypopituitarism

• Schizoaffective disorders

• Schizophrenia

• Somatic symptom disorders

Prognosis

Major depression has very high morbidity and mortality contributing to high rates of suicide. Even though effective drug treatment is available, nearly 50% may not initially respond. Complete remission is not common but at least 40% achieve partial remission in 12 months.

However, relapses are common and many patients require a variety of treatments to control the symptoms. The quality of life of most patients with depression is poor.

Depression accounts for nearly 40,000 cases of suicide each year in the US. The highest rate of suicides is in older men.

Enhancing Healthcare Team Outcomes

Depression is a very common disorder encountered by the nurse practitioner, primary care provider, psychiatrist, and mental health worker, coordinating as an interprofessional healthcare team. The disorder has extremely high morbidity including the risk of suicide. All healthcare workers should be knowledgeable about this disorder and refer the patient to a psychiatrist if there is a risk of self-harm.

Education plays an important role in the successful treatment of major depressive disorder. This would include the education of the family and the patient. Lack of accurate information and misperceptions of the illness as a personal weakness or failings leads to painful stigmatization and avoidance of the diagnosis by many of those affected. Patients should know the rationale behind the choice of treatment, potential adverse effects, and expected results.

The involvement of the pharmacist in the treatment plan can enhance medication compliance and referral for psychotherapy. The pharmacist can also check that dosing is appropriate, that there are no significant interactions, and counsel on adverse effects. Engaging family members can be a critical component of a treatment plan. Family members are helpful informants, can ensure medication compliance, be a big source of social support and can encourage patients to change behaviors that perpetuate depression (e.g., inactivity).

Patients with moderate to severe depression should also be seen by a social worker or case management nurse to ensure that they have a support system and finances for treatment. If there is a concern, the person managing the case should present the issues to the interprofessional team so that a plan can be developed to get the patient the care they need.  Overall, depression is managed by an interprofessional team dedicated to the management of mental health disorders. Open communication between all the members of the interprofessional team is the key to lowering the morbidity of the disorder. [Leve 5]

Outcomes

The outcomes for patients with depression are guarded. There is no cure and the condition has frequent relapses and remissions, leading to a poor quality of life.[3][12][13]

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Salik I, Marwaha R. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Sep 19, 2022. Electroconvulsive Therapy. [PubMed: 30855854]

2.

Singh R, Volner K, Marlowe D. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jun 12, 2023. Provider Burnout. [PubMed: 30855914]

3.

Ormel J, Kessler RC, Schoevers R. Depression: more treatment but no drop in prevalence: how effective is treatment? And can we do better? Curr Opin Psychiatry. 2019 Jul;32(4):348-354. [PubMed: 30855297]

4.

Pham TH, Gardier AM. Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies. Pharmacol Ther. 2019 Jul;199:58-90. [PubMed: 30851296]

5.

Namkung H, Lee BJ, Sawa A. Causal Inference on Pathophysiological Mediators in Psychiatry. Cold Spring Harb Symp Quant Biol. 2018;83:17-23. [PubMed: 30850434]

6.

Mangla K, Hoffman MC, Trumpff C, O'Grady S, Monk C. Maternal self-harm deaths: an unrecognized and preventable outcome. Am J Obstet Gynecol. 2019 Oct;221(4):295-303. [PubMed: 30849358]

7.

Shelton RC. Serotonin and Norepinephrine Reuptake Inhibitors. Handb Exp Pharmacol. 2019;250:145-180. [PubMed: 30838456]

8.

Tanner J, Zeffiro T, Wyss D, Perron N, Rufer M, Mueller-Pfeiffer C. Psychiatric Symptom Profiles Predict Functional Impairment. Front Psychiatry. 2019;10:37. [PMC free article: PMC6396718] [PubMed: 30853916]

9.

Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry. 2019 Jun;6(6):538-546. [PubMed: 30850328]

10.

Knappe S, Einsle F, Rummel-Kluge C, Heinz I, Wieder G, Venz J, Schouler-Ocak M, Wittchen HU, Lieb R, Hoye J, Schmitt J, Bergmann A, Beesdo-Baum K. [Simple guideline-oriented supportive tools in primary care: Effects on adherence to the S3/NV guideline unipolar depression]. Z Psychosom Med Psychother. 2018 Sep;64(3):298-311. [PubMed: 30829159]

11.

Saracino RM, Nelson CJ. Identification and treatment of depressive disorders in older adults with cancer. J Geriatr Oncol. 2019 Sep;10(5):680-684. [PMC free article: PMC7457378] [PubMed: 30797709]

12.

Hengartner MP, Passalacqua S, Andreae A, Heinsius T, Hepp U, Rössler W, von Wyl A. Antidepressant Use During Acute Inpatient Care Is Associated With an Increased Risk of Psychiatric Rehospitalisation Over a 12-Month Follow-Up After Discharge. Front Psychiatry. 2019;10:79. [PMC free article: PMC6396716] [PubMed: 30853919]

13.

Rootes-Murdy K, Carlucci M, Tibbs M, Wachtel LE, Sherman MF, Zandi PP, Reti IM. Non-suicidal self-injury and electroconvulsive therapy: Outcomes in adolescent and young adult populations. J Affect Disord. 2019 May 01;250:94-98. [PubMed: 30844603]

Disclosure: Suma Chand declares no relevant financial relationships with ineligible companies.

Disclosure: Hasan Arif declares no relevant financial relationships with ineligible companies.